Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lantern Pharma Inc (NQ: LTRN ) 6.070 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, May 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 425 Open 6.070 Bid (Size) 5.850 (2) Ask (Size) 6.350 (1) Prev. Close 6.070 Today's Range 6.070 - 6.070 52wk Range 2.380 - 11.99 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 12 Health Care Stocks Moving In Monday's After-Market Session May 13, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's After-Market Session May 10, 2024 Via Benzinga Performance YTD +45.56% +45.56% 1 Month +12.83% +12.83% 3 Month +55.24% +55.24% 6 Month +50.55% +50.55% 1 Year +28.06% +28.06% More News Read More LTRN Stock Earnings: Lantern Pharma Misses EPS for Q1 2024 May 09, 2024 Via InvestorPlace Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights May 09, 2024 From Lantern Pharma Inc. Via Business Wire Recap: Lantern Pharma Q4 Earnings March 18, 2024 Via Benzinga Lantern Pharma Earnings Preview March 15, 2024 Via Benzinga Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism May 06, 2024 From Lantern Pharma Inc. Via Business Wire Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET May 02, 2024 From Lantern Pharma Inc. Via Business Wire 3 Machine Learning Stocks with the Potential to Make You an Overnight Millionaire May 01, 2024 Via InvestorPlace Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development April 24, 2024 From Lantern Pharma Inc. Via Business Wire Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan April 22, 2024 From Lantern Pharma Inc. Via Business Wire Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket April 19, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session April 11, 2024 Via Benzinga Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth April 10, 2024 Via FinancialNewsMedia Topics Artificial Intelligence Exposures Artificial Intelligence Product Safety AI Sector Stalling: Only 4 Of 7 Categories Went Up In March March 31, 2024 Via Talk Markets Topics Artificial Intelligence Exposures Artificial Intelligence Six Of Seven AI Stock Categories Increased This Week March 23, 2024 Via Talk Markets Topics Artificial Intelligence Exposures Artificial Intelligence Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028 March 20, 2024 Via FinancialNewsMedia Topics Artificial Intelligence Exposures Artificial Intelligence Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028 March 20, 2024 From FN Media Group LLC Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's Intraday Session March 19, 2024 Via Benzinga LTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023 March 18, 2024 Via InvestorPlace Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights March 18, 2024 From Lantern Pharma Inc. Via Business Wire Earnings Scheduled For March 18, 2024 March 18, 2024 Via Benzinga Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284 March 15, 2024 From Lantern Pharma Inc. Via Business Wire 12 Health Care Stocks Moving In Monday's Intraday Session March 11, 2024 Via Benzinga Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET March 11, 2024 From Lantern Pharma Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
